Core Viewpoint - Meili Tianyuan Medical Health (02373) saw its stock price rise over 5%, reaching a new high of 35.06 HKD, driven by strong financial performance and market sentiment [1] Financial Performance - For the six months ending June 30, 2025, the company reported revenue of 1.459 billion RMB, a year-on-year increase of 28.2% [1] - The profit attributable to the company's owners was 156 million RMB, reflecting a year-on-year growth of 34.9% [1] - Basic earnings per share were reported at 0.68 RMB [1] - Revenue from beauty and health services amounted to 807 million RMB, up 29.6% year-on-year [1] - Revenue from sub-health medical services reached 150 million RMB, showing a significant increase of 107.8% year-on-year [1] Market Position and Strategy - Huatai Securities highlighted that the company's evolving "dual beauty + dual health" business model is expected to benefit from the rising consumer awareness among women regarding self-care [1] - Since 2025, several Class III medical device products have received NMPA approval for use in the medical beauty sector, indicating ongoing innovation and regulatory support [1] - Continuous advancements in upstream research and development, including effective raw materials, photonic instruments, and AI skincare, are anticipated to enhance the product offerings of leading downstream institutions [1] - The firm maintains a buy rating on the stock, reflecting confidence in the company's growth trajectory [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373) has seen a significant stock price increase, reaching a new high of 35.06 HKD, driven by strong financial performance and market sentiment [1] Financial Performance - For the six months ending June 30, 2025, the company reported revenue of 1.459 billion RMB, representing a year-on-year growth of 28.2% [1] - The profit attributable to the company's owners was 156 million RMB, up 34.9% year-on-year, with basic earnings per share of 0.68 RMB [1] - Revenue from beauty and health services amounted to 807 million RMB, reflecting a year-on-year increase of 29.6% [1] - Revenue from sub-health medical services reached 150 million RMB, showing a substantial year-on-year growth of 107.8% [1] Market Trends and Business Model - The company is benefiting from the rising consumer awareness of self-care among women, supported by its evolving "dual beauty + dual health" business model [1] - Since 2025, multiple Class III medical device products have received NMPA approval for use in the medical beauty sector, indicating ongoing innovation and regulatory support [1] - Continuous advancements in upstream research and development, including effective raw materials, photonic instruments, and AI skincare, are expected to enhance the product offerings of leading downstream institutions [1]